arrow
J

Jay S. Raval

University of Vermont
H指数:34
被引数:3,433

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In reply

回复

2026-09-300
PRE
Clinical significance of anti-M in pregnancy and self-reported ancestry: The BEST collaborative study

抗-M抗体在妊娠中的临床意义及自报祖源:BEST协作研究

2026-04-060
PRE
Transfusion-related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the MINT trial

限制性或宽松性输血策略患者的输血相关不良事件。MINT试验分析

2025-11-260
OAAI
Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in North America: Variable practices observed from July 2016 to June 2021, The BEST Collaborative Study

2016年7月至2021年6月期间北美冷沉淀生产及冷沉淀和纤维蛋白原浓缩物使用情况调查:最佳协作研究(The BEST Collaborative Study)观察到的不同实践模式

2025-09-280
PRE
Why do people still make anti-D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study

为什么在引入Rho(D)免疫球蛋白50多年后,人们仍然会产生抗-D?一项“为更安全的输血而努力的生物医学卓越”(Biomedical Excellence for Safer Transfusion, BEST)协作研究

2025-03-100
OA
Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis
2024-09-120
PRE
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes
2024-08-131
OAAI
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
2024-03-143
OA
A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura

一种预测免疫介导的血栓性血小板减少性紫癜死亡率的机器学习方法

2024-03-011
OAAI
A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry

USTMA TTP注册表中免疫性血栓性血小板减少性紫癜的致命结果的描述性分析

2024-01-262
OAAI
Early antibody treatment, inflammation, and risk of post-COVID conditions (vol 14, pg e00618, 2023)
MBIO
IF4.7
2024-01-160
OAAI
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
2024-01-115
OAAI
Red Blood Cell Transfusion
2023-11-2178
OA
Early antibody treatment, inflammation, and risk of post-COVID conditions
MBIO
IF4.7
2023-10-3111
OAAI